Mar. 18 at 4:12 PM
$PPBT
Trills always skip the only number that matters: MARKET CAP. Reverse splits donât change a companyâs value â they just change the share count.
Here are the facts:
⢠A
$30 target after the RS is the same valuation as a
$3 target before it
⢠A
$34 target before the RS is the same valuation as a
$340 target after it
⢠Analysts adjust perâshare targets automatically when the share count changes
⢠Nothing about the science or valuation changed because of the RS
The real story is this:
PB is trading at a ~
$4M market cap with two validated triâspecific antibodies, commercialâgrade manufacturing, clean tox, runway into 2027, and now independent validation of CMâ24 in EGFRâmutant lung cancer.
Thatâs the disconnect â not the share count.
Troll math is loud.
Actual valuation is quiet.
But valuation always wins.
